News

Barbara McElroy, MSN, CRNI, VA-BC, discussed best practices for creating an infusion center at the National Infusion Center Association Annual Conference.

DaxibotulinumtoxinA for Injection will provide long-lasting results with fewer injection treatments over time.

New sticky tape study can help predict onset of pediatric atopic eczema in babies.

Arcutis to present data from topical roflumilast clinical program at EADV 2022 Congress.

As we continue to face the COVID-19 pandemic and its long-term consequences, it is more important than ever for providers to build trust with patients.

Move comes after FDA give emergency use authorization for bivalent vaccines.

Sarah Higgins, DNP, APRN, WHNP-BC, discusses the best career advice she ever got, what she believes is the biggest myth in the aesthetic industry, and what changes she would like to see take place in the field of aesthetic dermatology.

ICYMI, this week we had stories about non-prescription acne treatments, clinical study results, pediatric atopic dermatitis, and the EADV 2022 Congress.

Revelle Aesthetics’ cellulite reduction device helps address frustrating aesthetic concerns.

AnaptysBio will refocus R&D efforts on its immune cell modulator pipeline.

Topline data expected in the first half of 2023.

Abstracts will include updates on treatment for psoriatic arthritis, psoriasis, atopic dermatitis, and more.

Positioning your portfolio for price stability and growth.

New research by the National Eczema Association has revealed the importance of patient input into treatment decisions.

ICYMI, this week we had stories about adherence issues in acne treatment, shin guard dermatitis, atopic dermatitis in skin of color patients, clinical trial news from Arcutis Biotherapeutics, and more.

Domestic production to begin at Michigan-based pharmaceutical maker.

Emergency Use Authorization provides a 2-dose primary series given 3 weeks apart.

ICYMI, this week we had stories about psoriasis and tattoos, shin guard dermatitis, rosacea symptoms, a new treatment option for severe burns, and more.

Physicians groups, analysts, have praised insurance premium subsidies, Medicare drug cost caps.

MediWound’s new burn care therapy alleviates risks associated with surgical debridement.

ICYMI, this week we had stories about product recalls, FDA warning letters, pediatric atopic dermatitis, acne treatment, and more.

VYNE Therapeutics Inc. announced the results of study VY2021-01.

Amazon, Ariella Naturals, and Justified Laboratories received warning letters from the FDA.

Edgewell Personal Care Company issued a voluntary national recall of 3 collections of Banana Boat Hair & Scalp Sunscreen due to the presence of benzene.

White House ramps up efforts to fight outbreak.

ICYMI, this week we had stories about FDA approvals, biologics vs biosimilars, CTCL treatment, atopic dermatitis in patients with skin of color, and more.

Click to see a preview of what to expect this week.

ICYMI, this week we had stories about legal issues in practices, sustainable skin care, acne scar treatments, monkeypox, and more.

A healthy 14-year old boy was evaluated for an intensely pruritic shin rash that developed 2 weeks prior and had been treated with oral antibiotics for 10 days.

What we know about monkeypox in pregnancy, including treatment recommendations, vaccination, and postpartum care.